Alnylam Pharmaceuticals
ALNY
#449
Rank
โ‚น4.733 T
Marketcap
โ‚น35,826
Share price
-0.32%
Change (1 day)
72.96%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): โ‚น15.44

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น8.07. In 2023 the company made an earnings per share (EPS) of -โ‚น316.64 an increase over its 2022 EPS that were of -โ‚น833.30.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น15.44
2023-โ‚น316.64-62%
2022-โ‚น833.3029.03%
2021-โ‚น645.83-3.36%
2020-โ‚น668.26-8.48%
2019-โ‚น730.157.67%
2018-โ‚น678.1239.74%
2017-โ‚น485.2712.94%
2016-โ‚น429.6638.84%
2015-โ‚น309.46-32.88%
2014-โ‚น461.05259.44%
2013-โ‚น128.27-31.25%
2012-โ‚น186.57

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
-โ‚น112.12-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
โ‚น3,897 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น245.78-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น21.53-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น65.48-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
โ‚น660.18 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น332.40 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
โ‚น56.51 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel